New paper in Exp & Clin Psychopharm: Trials on cannabis for chronic pain often miss what matters most to patients: sleep, coping, function, opioid substitution. Time to look beyond pain scores. 👉 https://t.co/khIg52NB2c w/ @Dr_Moon90@David_NeverDave
Teaching/learning intro stats and R? #rstats
Explore my teaching materials, including syllabus, lecture slides, exercises, interactive graphs, and self-graded review exercises: https://t.co/YwGJttsk9y
Instructors using DSS: source files from PUP have just been updated!
In response to requests from my students, I’ve built out comprehensive glossaries for my #MachineLearning and #DataAnalytics courses. It took a lot of work, but I’m absolutely stoked to share these as free resources in my open-access e-books.
📘 Data Analytics and Geostatistics Glossary
🔗 https://t.co/dgjNwFEQgb
🤖 Machine Learning Glossary
🔗 https://t.co/QVvBu9vR2b
I hope these glossaries help students and practitioners alike navigate key concepts more easily. Feedback is always welcome!
Do you want to capture health behavior as it happens? My summer institute on EMA is coming up at the end of this month. Spots are limited - don't miss out! @JohnsHopkinsDMH@JohnsHopkinsSPH
Original: @RubensteinDana& colleagues (@DukeMedSchool, @DukePsychiatry) analyzed momentary data reported throughout the day by people with back pain who smoke
— Novel insights into short-term relationships between pain and smoking
Full: https://t.co/pQTiWO9I6a
Six decades ago, hope surged for depression and opioid addiction treatments. Today, depression management has advanced significantly, while progress in #OUD treatment has been more gradual.
@DrKellyDunn explores this in a @medpagetoday#opinion piece: https://t.co/eWnFmstjzI.
@kirstenelins Again, examining chronic pain within the context of kratom research appears to be critical. I hope we can pursue this research soon with KEMA 2.0!
Academics are paid nothing for peer review.
Yet journals made a total of over $8.3 billion on article processing charges alone between 2019-2023.
Make it make sense.
Eight years after releasing the 2016 opioid guideline and two years after revising it, @CDCgov is finally making plans for a review of the guideline’s impact on #patients, caregivers, #doctors, and the practice of pain medicine. #chronicpain@CDCInjury https://t.co/2ap9SGUts5
Now in Pain Reports: “Assessing alexithymia in chronic pain: psychometric properties of the Toronto Alexithymia Scale-20 and Perth Alexithymia Questionnaire” https://t.co/H3zX4Yrmul
Now in Pain Reports: “Assessing alexithymia in chronic pain: psychometric properties of the Toronto Alexithymia Scale-20 and Perth Alexithymia Questionnaire” https://t.co/xAPvnZRBtv
9. Restoring communication in motor neuron disease
In a patient with motor neuron disease (ALS) and loss of speech as a result, a brain implant read the neural activity of his attempted speech and produced it via a computer - in his own voice: